Global Analysis Finds High Prevalence of Osteoporosis in Men with Prostate Cancer

A new global analysis indicates that one in five men with prostate cancer has osteoporosis, and more than six in ten may have bone density below the normal range. This is largely attributed to androgen-deprivation therapy (ADT), a standard treatment for advanced prostate cancer, which suppresses testosterone and accelerates bone mineral density decline.